Get a clear picture of Alzheimer’s disease pathology.
Leverage a single test that has high concordance with amyloid PET status1
Remove diagnostic testing barriers with a simple blood draw
Gain accurate insights with a clinically-validated algorithm that combines Aβ42/40 and p-tau217/np-tau217 (%p-tau217) ratios
Get clear answers with Positive or Negative results that reflect high or low likelihood for the presence of brain amyloid pathology
Powerful performance.
Proven performance of the PrecivityAD2™ test derives from the clinically-validated algorithm using a single cutoff that combines both the Aβ42/40 ratio and the p-tau217/np-tau217 ratio (%p-tau217) to help give you accurate insights into your patient's condition with a convenient blood draw.1
88% sensitivity
89% specificity
0.94 AUC-ROC
Making testing more accessible to more patients.
As a healthcare provider, you now have multiple blood draw options for your patients. These convenient choices include:
Scheduling a draw at one of the patient service centers available nationwide
Using a mobile phlebotomy service to visit the patient's home
Facilitating blood draws in office with your phlebotomist
Clinical validation of the
PrecivityAD2™ blood test
Get in touch
If you are a healthcare provider interested in ordering a PrecivityAD2™ test or have a question, complete the form and a C₂N Diagnostics staff member will be in touch soon.